[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
In: Opinions & Features

4.19.2012 | ABC News

A Case for Accelerating Regenerative Medicine

By Steve Brozak, Salman Punekar, and Emad Samad

Early in March 2012, 77-year-old Richard Poling entered a clinic in Bonita Springs, Florida for a stem cell treatment to help with age related heart and lung conditions.  Mr. Poling, an avid golfer and family man from Indiana, had sought several conventional therapies to alleviate his suffering with unsatisfactory results and was desperate for a treatment that would allow him to enjoy his life again. Shortly after receiving his treatment, however, Mr. Poling went into cardiac arrest at the clinic and passed away. According to investigators, the alleged stem cell treatment Mr. Poling received was not approved by the FDA.

For the full article, please click here.